Electric activity of the brain at early and late clinical stages of experimental modeling of Parkinson’s disease, an impact of hemantane

Close metadata

ABSTRACT

OBJECTIVE

To study an influence of the adamantane derivative hemantane on the electrical activity of the brain structures of mice at the early and late (severe) stages of experimental modeling of Parkinson’s disease (PD).

MATERIAL AND METHODS

For experimental modeling of PD in C57BL/6J mice, 30 male C57BL/6J mice weighing 25—32 g were systemically (intraperitoneally) administered proneurotoxin MPTP in two modes corresponding to different clinical stages of the disease: 1-methyl-4-phenyl-1.2.3.6-tetrahydropyridine (MPTP) at a dose of 12 mg/kg, 4 times and 20 mg/kg, 4 times with an interval of 2 hours, respectively.

RESULTS

At the early and late clinical stages of experimental modeling of PD in the brain structures of mice (sensorimotor cortex, substantia nigra, caudate nucleus), EEG desynchronization, an increase in wave amplitude, and an increase in the power spectrum in the range of delta frequencies and beta frequencies are observed at the late symptomatic stage experimental model of PD along with a decrease in electrical activity in the range of 4—12 Hz. Preliminary application of the adamantane derivative hemantane at a dose of 20 mg/kg, both in the early and late clinical stages of PD, prevented an excessive increase in the amplitudes of all groups of waves, normalized theta activity in the range of 4—12 Hz, reduced pathological slowing and dysregulation activity in the ranges delta and beta waves, with the prevalence of these effects in the substantia nigra of the brain of animals.

CONCLUSION

The effect of hemantane is more pronounced at the early clinical stage of experimental modeling of PD than at the later (full-scale) stage.

Keywords:

Parkinson’s disease

hemantane

experimental modeling of Parkinson’s disease

MPTP

electroencephalography

sensorimotor cortex

substantia nigra

caudate nuclei

Authors:

Voronina N.A.

Institute of General Pathology and Pathophysiology

ORCID: 0000-0002-1764-6444

Kapitsa I.G.

Federal Research Center For Innovator And Emerging Biomedical And Pharmaceutical Technologies

ORCID: 0000-0003-4487-0991

Kucheryanu V.G.

Institute of General Pathology and Pathophysiology

ORCID: 0000-0002-5071-3581

Goloborshchova V.V.

Institute of General Pathology and Pathophysiology

ORCID: 0000-0003-2540-4303

Voronina T.A.

Federal Research Center For Innovator And Emerging Biomedical And Pharmaceutical Technologies

SPIN RSCI: 5766-3452
Scopus AuthorID: 7103337584
ResearcherID: A-5990-2017
ORCID: 0000-0001-7065-469X

Received:

10.04.2024

Accepted:

28.05.2024

List of references:

Costa HN, Esteves AR, Empadinhas N, et al. Parkinson’s Disease: A Multisystem Disorder. Neurosci Bull. 2023;39(1):113-124. https://doi.org/10.1007/s12264-022-00934-6
Alvarez D, Hornero R, Marcos J, et al. Spectral analysis of electroencephalogram and oximetric signals in obstructive sleep apnea diagnosis. Annu Int Conf IEEE Eng Med Biol Soc. 2009;2009:400-403. https://doi.org/10.1109/IEMBS.2009.5334905
Stvolinsky SL, Kukley ML, Dobrota D, et al. Carnosine: an endogenous neuroprotector in the ischemic brain. Cell Mol Neurobiol. 1999;19(1):45-56. https://doi.org/10.1023/a:1006960407008
Neufeld MY, Inzelberg R, Korczyn AD. EEG in demented and non-demented parkinsonian patients. Acta Neurol Scand. 1988;78(1):1-5. https://doi.org/10.1111/j.1600-0404.1988.tb03609.x
Ayele BA, Tesfaye H, Wuhib MZ, et al. Factors Associated with EEG Slowing in Individuals with Parkinson’s Disease. Ethiop J Health Sci. 2022;32(1):73-80.
Stoffers D, Bosboom JLW, Deijen JB, et al. Slowing of oscillatory brain activity is a stable characteristic of Parkinson’s disease without dementia. Brain. 2007;130(7):1847-1860. https://doi.org/10.1093/brain/awm034
Nerobkova LN, Voronina TA, Katunina EA, et al. Features of the effects of amantadine on the spatial organization of biopotentials of the brain of patients with parkinsonism. Psikhofarmakologiya i biologicheskayanarkologiya. 2002;2(3):429. (In Russ.).
Arakelyan RK, Nerobkova LN, Katunina EA, et al. Features of the functional activity of the brain in patients with Parkinson’s disease during treatment with amantadine sulfate. S.S. Korsakov Journal of Neurology and Psychiatry. 2005;105(4):17-21. (In Russ.).
Waninger S, Berka C, Stevanovic KM, et al. Neurophysiological Biomarkers of Parkinson’s Disease. J Parkinsons Dis. 2020;10(2):471-480. https://doi.org/10.3233/JPD-191844
Weinberger M, Mahant N, Hutchison WD, et al. Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson’s disease. J Neurophysiol. 2006;96(6):3248-3256. https://doi.org/10.1152/jn.00697.2006
Nerobkova LN, Val’dman EA, Voronina TA, et al. The effect of a new derivative of aminoadamantan A 7 on the manifestations of parkinsonian syndrome caused by systemic administration of the neurotoxin MPTP Eksperimental’naya i klinicheskayafarmakologiya. 2000;3:3. (In Russ.).
Devergnas A, Pittard D, Bliwise D, et al. Relationship between oscillatory activity in the cortico-basal ganglia network and parkinsonism in MPTP-treated monkeys. Neurobiol Dis. 2014;68:156-166. https://doi.org/10.1016/j.nbd.2014.04.004
Voronina NA, Kucheryanu VG, Kapitsa IG, Voronina TA. Effects of adamantane derivatives on behavioral activity of mice with different stages of experimental parkinsonian syndrome. Patogenez [Pathogenesis]. 2019;17(4):57-62. (In Russ.). https://doi.org/10.25557/2310-0435.2019.04.57-62
Val’dman EA, Voronina TA, Aksenova LN, et al. The effect of the new antiparkinsonian drug Hemantane on monoamine oxidase activity. Eksperimental’naya i klinicheskaya farmakologiya. 2003;66:5:3-5. (In Russ.).
Voronina TA, Raevskii KS, Kudrin VS, et al. The effect of a new potential antiparkinsonian agent himantan on the content of monoamines and their metabolites in the rat striatum. Eksperimental’naya i klinicheskaya farmakologiya. 2001;6:13-16. (In Russ.).
Ivanova EA, Kapitsa IG, Zolotov NN, et al. Effects of Hemantane upon the level of lipid peroxidation in brain in experimental parkinsonian syndrome. Farmakokinetika I farmakodinamika. [Pharmacokinetics and Pharmacodynamics]. 2016;79(3):9-12. (In Russ.).
Voronina NA, Kucheryanu VG, Vetrile LA, et al. The effect of hemantane on the level of pro-inflammatory cytokines in the nigrocaudate complex of the brain of mice with experimental parkinsonism. Patogenez [Pathogenesis]. 2021;19(2):45-49. (In Russ.). https://doi.org/10.25557/2310-0435.2021.02.45-49
Voronina NA, Lisina OYu, Krasilnikova IA, et al. Influence of Hemantane on changes in Ca2+ and Na+ caused by activation of NMDA channels in cultured rat brain neurons. Neurochemical Journal. 2021;(1):8-17. https://doi.org/10.1134/S1819712421010165
Ugrumov MV, Khaindrava VG, Kozina EA, et al. Modeling of presymptomatic and symptomatic stages of parkinsonism in mice. Neuroscience. 2011;181:175-188. https://doi.org/10.1016/j.neuroscience.2011.03.007
Khaindrava VG, Kozina EA, Kucheryanu VG, et al. Modeling of preclinical and early clinical stages of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2010;110(7):41-47. (In Russ.).
Paxinos G, Franklin KBJ. The mouse brain in stereotaxic coordinates. 2nd ed. Publisher, Academic press; 2001;264.
Mitrofanov AA. Komp’yuternaya sistema analiza i topograficheskogo kartirovaniy aelektricheskoi aktivnosti mozga s neirometricheskim bankom EEG-dannykh «Brainsys». M.: Nauchno-meditsinskaya firma «Statokin»; 2007;72. (In Russ.).
Buzsáki G, Buhl DL, Harris KD, et al. Hippocampal network patterns of activity in the mouse. Neuroscience. 2003;116(1):201-211. https://doi.org/10.1016/s0306-4522(02)00669-3
Singh A. Oscillatory activity in the cortico-basal ganglia-thalamic neural circuits in Parkinson’s disease. Eur J Neurosci. 2018;48(8):2869-2878. https://doi.org/10.1111/ejn.13853
Soikkeli R, Partanen J, Soininen H, et al. Slowing of EEG in Parkinson’s disease. Electroencephalogr ClinNeurophysiol. 1991;79(3):159-165. https://doi.org/10.1016/0013-4694(91)90134-p
Chen H, Lei H, Xu Q. Neuronal activity pattern defects in the striatum in awake mouse model of Parkinson’s disease. Behav Brain Res. 2018;341:135-145. https://doi.org/10.1016/j.bbr.2017.12.018
Hutchison WD, Dostrovsky JO, Walters JR, et al. Neuronal oscillations in the basal ganglia and movement disorders: evidence from whole animal and human recordings. J Neurosci. 2004;24(42):9240-9243. https://doi.org/10.1523/JNEUROSCI.3366-04.2004
He X, Zhang Y, Chen J, et al. The patterns of EEG changes in early-onset Parkinson’s disease patients. Int J Neurosci. 2017;127(11):1028-1035. https://doi.org/10.1080/00207454.2017.1304393
Kapitsa IG, Kokshenev II, Nerobkova LN, et al. The effect of himantan on the bioelectric activity of the brain of mice with MPTP — induced Parkinsonian syndrome. Eksperimental’naya i klinicheskaya farmakologiya. 2013;4:3-6. (In Russ.).
Kapitsa IG, Nerobkova LN, Voronina TA. EEG correlates of an early stage of a Parkinson illness in experiment on mice of the strain C57BL/6. Biomeditsina. 2014;1(1):54-60. (In Russ.).

Close metadata